Vaccine delivery devices

Patent metadata

Field	Value
Publication number	US-10130454-B2
Application number	US-201514814148-A
Country	US
Kind code	B2
Filing date	Jul 30, 2015
Priority date	Aug 1, 2014
Publication date	Nov 20, 2018
Grant date	Nov 20, 2018

Abstract

This document provides vaccine delivery devices and methods for vaccinating an animal (e.g., a mammal). For example, vaccine delivery devices that include a container having one or more openings, a vaccine depot located within the container, and a diffusion barrier located within the container in a manner such that material (e.g., an antigenic vaccine component) within the vaccine depot must pass through the diffusion barrier before reaching one of the openings are provided.

First claim

What is claimed is:

1. An implantable vaccine delivery device comprising:
(a) a container having a portion of its surface define porous openings that restrict intact cells from passing in and out of said container and that permit antibodies to pass in and out of said container,
(b) a vaccine depot comprising an antigen and located within said container, and
(c) a barrier material located within said container in a position wherein said antigen of said vaccine depot must travel through said barrier material to reach said porous openings, wherein said barrier material allows free antibodies and free antigen to pass through said barrier material, and wherein said barrier material prevents antibody-antigen complexes from passing through said barrier material.

2. The device of claim 1 , wherein said container comprises a polyvinylidene difluoride membrane defining said porous openings.

3. The device of claim 1 , wherein said porous openings are about 0.66 μm in diameter.

4. The device of claim 1 , wherein said vaccine depot comprises 1,6-bis(p-carboxyphenoxy) hexane (CPH).

5. The device of claim 4 , wherein said vaccine depot comprises CPTEG and CPH in a 20:80 ratio.

6. The device of claim 1 , wherein said vaccine depot comprises 1,6-bis(p-carboxyphenoxy) hexane (CPH) and sebacic acid (SA).

7. The device of claim 6 , wherein said vaccine depot comprises CPH and SA in a 80:20 ratio.

8. The device of claim 1 , wherein said barrier material comprises collagen.

9. The device of claim 1 , wherein said barrier material comprises hydroxyapatite.

10. The device of claim 1 , wherein said barrier material defines pores about 40 to about 60 nm in diameter.

11. The device of claim 1 , wherein said barrier material defines pores about 50 nm in diameter.

12. A method for vaccinating an animal, wherein said method comprising implanting a vaccine delivery device into said animal, wherein said vaccine delivery device comprises:
(a) a container having a portion of its surface define porous openings,
(b) a vaccine depot comprising an antigen and located within said container, and
(c) a barrier material located within said container,
wherein cells within said animal are restricted from passing into said container,
wherein antibodies within said animal are allowed to pass into said container,
wherein said antigen of said vaccine depot must travel through said barrier material to reach said porous openings,
wherein said barrier material allows free antibodies and free antigen to pass through said barrier material, and
wherein said barrier material prevents antibody-antigen complexes from passing through said barrier material.

13. The method of claim 12 , wherein said animal is a dog or cat.

14. The method of claim 12 , wherein said antigen is gonadotropin-releasing hormone.

15. The method of claim 12 , wherein said container comprises a polyvinylidene difluoride membrane defining said porous openings.

16. The method of claim 12 , wherein said porous openings are about 0.22 μm in diameter.

17. The method of claim 12 , wherein said vaccine depot comprises 1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane (CPTEG) and 1,6-bis(p-carboxyphenoxy) hexane (CPH).

18. The method of claim 17 , wherein said vaccine depot comprises CPTEG and CPH in a 20:80 ratio.

19. The method of claim 12 , wherein said vaccine depot comprises 1,6-bis(p-carboxyphenoxy) hexane (CPH) and sebacic acid (SA).

20. The method of claim 19 , wherein said vaccine depot comprises CPH and SA in a 80:20 ratio.

21. The method of claim 12 , wherein said barrier material comprises collagen.

22. The method of claim 12 , wherein said barrier material comprises hydroxyapatite.

23. The method of claim 12 , wherein said barrier material defines pores about 40 to about 60 nm in diameter.

24. The method of claim 12 , wherein said barrier material defines pores about 50 nm in diameter.

Assignees

• Univ Iowa State Res Found Inc

Inventors

• Jones Douglas E
• Brewer Matthew
• Narasimhan Balaji
• Jackman John

Classifications

• A61D1/025 Primary

  Vaccination appliances (hypodermic syringes A61M) · CPC title

• A61K47/42

  Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein (oligopeptides having up to five amino acids {A61K47/183}; polyamino acids A61K47/34) · CPC title

• A61K39/0005

  Vertebrate antigens (from snakes A61K39/38) · CPC title

• A61K9/0024

  Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L) · CPC title

• A61K2039/552

  Veterinary vaccine · CPC title